

Dysregulation of the transcription factors SOX4, CFBF and SMARCC1 correlates with outcome of colorectal cancer

CL Andersen¹, LL Christensen¹, K Thorsen¹, T Schepeler¹, FB Sørensen², HW Verspaget³, R Simon⁴, M Kruhøffer¹, LA Aaltonen⁵, S Laurberg⁶ and TF Ørntoft^{*,1}

¹Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus N DK8200, Denmark; ²Department of Pathology, Aarhus University Hospital, Aarhus DK8000, Denmark; ³Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; ⁴Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg D-20246, Germany; ⁵Department of Medical Genetics, Biomedicum, University of Helsinki, Helsinki FI 00290, Finland; ⁶Department of Surgery, Aarhus University Hospital, Aarhus DK8000, Denmark

The aim of this study was to identify deregulated transcription factors (TFs) in colorectal cancer (CRC) and to evaluate their relation with the recurrence of stage II CRC and overall survival. Microarray-based transcript profiles of 20 normal mucosae and 424 CRC samples were used to identify 51 TFs displaying differential transcript levels between normal mucosa and CRC. For a subset of these we provide *in vitro* evidence that deregulation of the Wnt signalling pathway can lead to the alterations observed in tissues. Furthermore, in two independent cohorts of microsatellite-stable stage II cancers we found that high SOX4 transcript levels correlated with recurrence (HR 2.7; 95% CI, 1.2–6.0; $P=0.01$). Analyses of ~1000 stage I–III adenocarcinomas, by immunohistochemistry, revealed that patients with tumours displaying high levels of CFBF and SMARCC1 proteins had a significantly better overall survival rate ($P=0.0001$ and $P=0.0275$, respectively) than patients with low levels. Multivariate analyses revealed that a high CFBF protein level was an independent predictor of survival. In conclusion, several of the identified TFs seem to be involved in the progression of CRC.

British Journal of Cancer (2009) 100, 511–523. doi:10.1038/sj.bjc.6604884 www.bjcancer.com

Published online 20 January 2009

© 2009 Cancer Research UK

Keywords: gene expression; colorectal cancer; transcription factor; tissue microarray; clinical outcome

Colorectal cancer (CRC) accounts for about 13% of all cancers and it is the second most common cause of cancer death in the western world (Parkin, 2001). Patients presenting with stage II CRC (no lymph node or distant metastases) have a 5-year survival of 75–80% when surgically treated. Surgical resection is highly effective in localised disease, but a significant proportion of stage II patients (20–25%) experiences recurrence and dies from the disease. Currently, it is not possible to accurately differentiate between groups of stage II patients with good and poor prognosis; consequently, there is an acute need for biomarkers that can distinguish between these two groups (Wang *et al*, 2004). Molecularly, CRC can be divided into two major subgroups: microsatellite-stable (MSS) and -unstable cancers (MSI). The two subgroups have a different clinical disease course, but are otherwise very similar. The mechanism responsible for MSI is known to be a failure of the DNA mismatch repair system. Recently, whole-genome transcriptional profiling studies have shown that there are profound transcriptional differences between MSS and MSI cancers (Giacomini *et al*, 2005; Kruhoffer *et al*, 2005). However, the causal mechanisms for these differences

remain unclear. The biological and clinical behaviour of CRC is affected by multiple molecular pathways controlling cellular processes like differentiation, migration, replication, DNA repair, proliferation and apoptosis (Sancho *et al*, 2004); one particularly well-studied pathway is the Wnt pathway (de Lau *et al*, 2007). Ultimately, the transcriptional responses mediated by these pathways are controlled and exercised by transcription factors (TFs). In normal tissue, tight control of the levels of TFs is crucial to maintain tissue homeostasis and, hence, many TFs have been found to be oncogenic when their expression is deregulated or when their functionality is altered through fusion with other genes (Look, 1997). An improved understanding of which TFs affect cancer biology may lead to improved ability to predict clinical outcome and discovery of novel therapeutic strategies.

In this study, we used microarray expression profiling to identify 51 TFs significantly deregulated in CRC. The list included not only several TFs known to be deregulated in CRC but also many for which this information was novel. The expression of the 51 TFs was further investigated in relation to clinically important CRC subgroups. These analyses showed that 12 TFs were differentially expressed between the MSS and MSI tumour subgroups, that a high transcript level of one TF (SOX4) was significantly associated with poor outcome of stage II MSS cancer and that high protein levels of CFBF and SMARCC1 were correlated with increased overall survival of CRC. In relation to

*Correspondence: Professor TF Ørntoft; E-mail: orntoft@ki.au.dk
Received 1 October 2008; revised 15 December 2008; accepted 16 December 2008; published online 20 January 2009

the mechanisms causing the TF deregulation, we provide evidence that deregulation of the Wnt pathway influences the expression level of ~20% of the 51 TFs.

MATERIALS AND METHODS

Patients and samples

Colorectal samples from a total of 444 patients, comprising 20 adjacent normal mucosa and 424 primary colorectal carcinomas, were used for array-based transcriptional profiling. The 20 adjacent normal mucosa samples were all collected from non-cancer areas located orally for the tumour. None of the patients had received preoperative chemo- and/or radiotherapy. The samples were organised into two data sets. The first data set termed 'HG_U133A' is a subset of a previously published set of transcription profiles (Kruhoffer *et al*, 2005) and consisted of 10 adjacent normal mucosa and 80 colon cancer samples, comprising 53 stage II and 27 stage III cancers with a median age at diagnosis of 68.5 years (range 36–87 years). The MSS/MSI status was known for 76 of the 80 cancers (25 MSI and 51 MSS). The second data set termed 'HG_U133 plus 2.0' consisted of 10 adjacent normal mucosa and 344 cancer samples (288 located in the colon and 56 in the rectum). The cancer samples comprised 23 stage I, 287 stage II, 22 stage III and 12 stage IV cancers with a median age at diagnosis of 70 years (range 29–94 years). The MSS/MSI status was known for 331 of the 344 cancers (73 MSI and 258 MSS).

For the 'HG_U133 plus 2.0' set, time to recurrence information was available for 326 of the 332 stage I–III cancers. The median duration of follow-up was 59.8 months (range 12.8–145.6 months) for the 274 patients without recurrence as the first event and 18.7 months (range 1.2–78.7 months) for the 52 patients with distant recurrence as the first event.

Detailed lists of the clinicopathological data available for the 444 samples can be found in Supplementary Tables 1 and 2. Informed consent was obtained from all patients according to local ethical regulations, and all studies were approved by local ethical committees according to the Helsinki Declaration.

Three human colorectal carcinoma tissue microarrays (TMAs) were used for immunohistochemistry (IHC) analysis. A commercial TMA (catalogue no. COCA 912-5-OL; BioCat, Heidelberg, Germany) for the evaluation of associations of the normal adenoma-carcinoma sequence with 71 colorectal specimens (10 normal colon mucosa, 10 adenoma, 40 stage I–IV adenocarcinomas and 11 liver metastasis), a custom-made stage II TMA containing 51 stage II adenocarcinomas and 50 normal mucosa specimens, and a large custom-made TMA containing CRC biopsies from 1461 patients (Went *et al*, 2006). The latter TMA was used for survival analyses. Therefore, patients with missing values for any of the following parameters gender, age at surgery, tumour location, TNM stage and survival time were excluded. Likewise, patients who died of surgical complications (dead within 30 days of surgery) were excluded, leaving 1283 out of 1461 patients for survival analysis. Their median age at diagnosis was 71 years (range 30–96 years). The 1283 cancers comprised 177 stage I, 492 stage II and 614 stage III cancers. The median duration of follow-up was 52.4 months (range 1–152 months). Data on post-surgery radio- or chemotherapy were not available. Detailed clinicopathological data of the TMA specimens are given in Supplementary Tables 3A, 4 and 5. The WHO/UICC-TNM staging system was used for staging of the adenocarcinomas.

Labelling, hybridisation, normalisation and statistical analysis of microarrays

Labelling of RNA, hybridisation and scanning of HG_U133 plus 2.0 and Human Exon 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA)

were performed as described earlier (Dyrskjot, 2003; Thorsen *et al*, 2008). The Human Genome U133A GeneChip array-based transcription profiles used in this study is a subset of a previously published set of transcription profiles (Kruhoffer *et al*, 2005). GC-content corrected robust multiarray analysis (GC-RMA) normalisation of the U133 plus 2.0 arrays and iterPLIER normalisation of the Exon 1.0 ST arrays were performed using the software packages ArrayAssist (Stratagene, La Jolla, CA, USA) and Expression Console v1.1 (Affymetrix), respectively. Differentially expressed genes were identified using a Benjamini and Hochberg-corrected 'Two class unpaired' statistical tests.

Approach for the identification of transcriptionally deregulated TFs

A list of candidate TFs was generated by querying the Gene Ontology (GO) database for genes linked to the GO term 'transcription'. In this way, the Affymetrix HG_U133A array was found to contain probe sets for 1026 potential TFs (1026 unique Entrez Gene IDs). To identify if any of these candidate TFs were deregulated in CRC compared with normal mucosa, we used the two independent sets of array-based transcriptional profiles described in the 'Patients and samples' section. The candidate TFs with an average numerical log₂ fold change of at least 1 (1 on log₂ scale, corresponds to a fold change of 2 on a linear scale) that were significantly deregulated ($P < 10^{-4}$ after Benjamini and Hochberg correction) in the 'HG_U133A' set (80 cancers/10 normals) were taken further for validation in the second larger and independent set 'HG_U133 plus 2.0' (344 cancers/10 normals). Transcription factor deregulation was considered significant if a fold change of at least 1 (in the same direction as in the 'HG_U133A' set) with a *P*-value lower than 10^{-4} was obtained in the validation set.

Real-time RT-PCR

Quantitative real-time RT-PCR (qRT-PCR) was performed on a 7900HT Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using the relevant (TaqMan or SYBR Green) Master Mix (Applied Biosystems). Predesigned TaqMan assays were used to measure *RBI* (Hs01078066_m1) and *E2F3* (Hs00605457_m1) (Applied Biosystems). For normalisation, the gene *Ubiquitin C (UBC)* was employed. We have demonstrated earlier the suitability of *UBC* as a normalisation gene for analysis of normal mucosa and CRC specimen sample sets (Andersen *et al*, 2004). The *UBC* primer sequences have been published earlier (Andersen *et al*, 2004). cDNA was generated using the Superscript™ cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA) with random nonamer primers and RNase inhibitor (Ambion, Austin, TX, USA). Each measurement was performed in triplicate, and no-template controls were included for each assay. Relative expression values were obtained using a four-point 10-fold dilution curve. The dilution curve was created using a cDNA pool of each of the test cDNAs.

Cell culturing

Dominant-negative TCF1 (dnTCF1)-inducible LS174T-derived cell lines have earlier been described (van de Wetering *et al*, 2002) and were a kind gift from Dr Hans Clevers (The Hubrecht Laboratory, Utrecht, The Netherlands). The cell lines were cultured and dnTCF1 induced by doxycycline as described earlier (Scheperle *et al*, 2007). The cell lines were free from mycoplasma contamination as verified by the MycoSensor™ PCR assay kit (Stratagene) according to the manufacturer's instructions. Cells were harvested at 0 and 12 h after doxycycline induction. mRNA for array-based transcript profiling was extracted using the GenElute™ Mammalian total RNA miniprep kit (Sigma-Aldrich, Brandlay, Denmark).

Antibodies

Mouse monoclonal antibodies usable for IHC and immunoblotting were available for the TFs CBF β (catalogue no. ab11921 (clone 141,4,1); Abcam, Cambridge, UK), E2F3 (catalogue no. 05-551; Upstate, Charlottesville, VA, USA) and SMARCC1 (catalogue no. sc-32763 (DXD7); Santa Cruz Biotechnology, Santa Cruz, CA, USA). A rabbit polyclonal anti-Sox4 antibody (catalogue no. AB5803; Chemicon International Inc., Temecula, CA, USA) usable for IHC was also available.

The specificity of the E2F3 and SMARCC1 antibodies was validated by immunoblot analysis of COS7 cells transiently transfected with expression plasmids containing full-length cDNAs (Supplementary Figures 1A and B). The specificity of the CBF β antibody was validated by immunoblot analysis of normal mucosa and colon cancer, which yielded bands corresponding to the known CBF β isoforms (Supplementary Figure 1C). The SOX4 antibody did not work in western blot analysis. However, we have earlier used IHC to investigate SOX4 protein expression in bladder cancer (Aaboe *et al*, 2006). Hence, bladder cancer specimens were used as positive controls for the SOX4 antibody. A pan-leukocyte marker, CD45, in the form of the mouse monoclonal anti-CD45 antibody (catalogue no. MS-240-P1; Neomarkers/Lab Visions corp., Fremont, CA, USA) was used to identify infiltrating lymphocytes (Woodford-Thomas and Thomas, 1993).

Immunohistochemistry

Standard indirect staining procedures were used for IHC (Went *et al*, 2006). In brief, paraffin was removed followed by blocking of endogenous peroxidase activity, heat-induced epitope demasking and blocking to prevent unspecific binding. Then primary antibodies were applied; the following antibodies were used, anti-CBF β (1:1800), anti-SMARCC1 (1:150), anti-E2F3 (1:200), anti-SOX4 (1:800) and anti-CD45 (1:600). Detection was performed using the Envision system (DakoCytomation, Glostrup, Denmark). Finally, the sections were counterstained with haematoxylin.

Semiquantitative scoring of intensity (negative, 0; weak, 1; and strong, 2) and fraction of positive cancer cells (negative, 0; less than half, 1; and more than half, 2) was undertaken independently by two investigators. Nuclear and cytoplasmic staining was scored separately. Tissue microarray cores that were missing or contained fewer than 10 cancer cells or demonstrated significant artefacts were not scored. Kappa statistics was used to evaluate the agreement between the observers. In all scoring categories (intensity, fraction, nuclear and cytoplasmic) a good-to-very good inter-observer agreement was obtained for all investigated TFs (Kappa statistic values ranging from 0.73 to 1.00, median 0.90). The scores were converted into simple categories of negative, weak and strong staining using the following formula: negative: intensity 0 and fraction of positive cells 0; weak: intensity 1 and fractions 1 and 2, and intensity 2 and fraction 1; strong: intensity 2 and fraction 2.

Statistical analysis

The software used for statistical analysis was STATA 9.2 (StataCorp, College Station, TX, USA). Fisher's exact and χ^2 tests were used to compare TF expression and clinical and morphological tumour characteristics.

For each individual IHC score (nuclear and cytoplasmic), survival analysis was performed. For simplicity, the nuclear and cytoplasmic scores were combined when they showed the same statistical trend. The scores were combined using the following formula: negative: both scores were negative; weak: if neither score was strong and one or both were weak; and strong: one or both scores were strong. Survival curves were plotted according to

Kaplan–Meier. Univariate analysis was performed using the log-rank test or the Cox proportional hazards model. Multivariate analysis was performed using the Cox proportional hazards regression model. *P*-values less than 0.05 were considered significant.

RESULTS

Identification of deregulated TF transcripts in colorectal cancer

By comparing transcript profiles of normal mucosa and CRC samples in two independent sample sets, covering a total of 20 normal mucosa and 424 adenocarcinoma samples, we identified 51 TFs that showed a significant ($P < 10^{-4}$, Benjamini and Hochberg corrected) fold change (of at least 2) from normal to cancer in both data sets. Fourteen of these TFs were downregulated and 37 upregulated (Table 1). The list included not only several TFs known to be deregulated in CRC, for example *c-MYC* (He *et al*, 1998) and *SOX9* (Blache *et al*, 2004), but also many for which this information was novel for example, CBF β and SMARCC1. Below we have validated four of the latter TFs, the others will have to be validated in future studies.

Transcriptional analysis of E2F3 and RB1

One of the 51 deregulated TFs was *E2F3*, which belongs to the family of E2F TFs. The E2F factors and the tumour suppressor RB1 constitute the key players in the RB/E2F pathway, a critical regulator of G1/S cell cycle transition and hence proliferation. Mutational inactivation of this checkpoint has been associated with many cancers, but not CRC (Nevins, 2001). Our transcript profiling data from the 'HG_U133 plus 2.0' data set (10 normal mucosa samples and 344 cancers) showed that the average *E2F3* transcript level was 1.67-fold (log₂ scale) higher in cancer than in normal mucosa (Table 1), whereas *RB1* remained unchanged ($P = 0.26$, two class unpaired test Benjamini and Hochberg corrected). A comparison of the *RB1/E2F3* transcript ratios revealed a significant reduction of -1.97 fold (log₂ scale) from normal mucosa to cancer ($P = 8.96 \times 10^{-8}$, Student's *t*-test). A similar reduction was found in the 'HG_U133A' data set (10 normal mucosa samples and 80 cancers) with the average *RB1/E2F3* ratio dropping -0.63 -fold (log₂ scale) from normal mucosa to cancer ($P = 0.019$, Student's *t*-test). To validate that the reduction was not an artefact of measuring the transcript levels using array technology, we selected 60 samples (10 normals and 50 randomly selected cancers) from the HG_U133 plus data set for qRT-PCR analysis. Quantitative RT-PCR confirmed that the *E2F3* transcript level was increased in cancer (2.22-fold, log₂ scale; $P = 1.26 \times 10^{-7}$, Student's *t*-test) and that the average *RB1/E2F3* ratio was reduced by -0.87 -fold (log₂ scale) from normal mucosa to cancer ($P = 3.52 \times 10^{-6}$, Student's *t*-test).

E2F3 IHC analysis of a commercial TMA containing normal mucosa as well as benign and malignant colorectal specimens revealed that E2F3 was significantly higher expressed also at the protein level in the majority of cancers compared with normal mucosa (Figure 1A–F). The data also indicated that the E2F3 protein level might be associated with tumour progression as a significant difference was observed between adenocarcinomas and metastases (Figure 1F). To investigate if the E2F3 protein level was associated with TNM stage and overall survival, IHC was applied to a large custom-made TMA with stage I–III adenocarcinomas, for which follow-up information was available. A borderline-significant association was found for TNM stage ($P = 0.066$, Fisher's exact test; Supplementary Table 3B). This resulted from a minor but significant shift from strong to weak E2F3 staining from stage I to II ($P = 0.011$, Fisher's exact test), which was not repeated from

Table 1 Fifty-one transcription factors deregulated in colorectal cancer

Gene symbol	Entrez gene ID	Probe set ID ^c	Transfac ID ^d	Transcription actor class ^d	'HG_UI33A' data set ^a		'HG_UI33 plus 2.0' data set ^b	
					P-value ^e	Fold change ^f	P-value ^e	Fold change ^f
HAND1	9421	220138_at	T04373	Basic helix-loop-helix	1.76E-05	-1.31	1.13E-09	-1.19
HIS1	10614	202815_s_at			9.84E-08	-1.15	4.22E-13	-1.67
KLF4	9314	220266_s_at		C2H2 zinc finger ^g	4.74E-05	-2.18	1.48E-09	-3.53
MAF	4094	206363_at		bZIP ^g	9.84E-08	-1.40	4.74E-22	-3.02
MEF2C	4208	209200_at	T01767	MADS box	1.17E-07	-1.96	1.36E-10	-2.86
NR1H4	9971	206340_at	T04498	Cys4 zinc finger of nuclear receptor type	2.40E-08	-2.70	4.17E-07	-1.92
NR3C2	4306	205259_at	T00513	Cys4 zinc finger of nuclear receptor type	3.52E-05	-2.20	7.39E-14	-4.02
NR5A2	2494	210174_at	T02771	Cys4 zinc finger of nuclear receptor type	1.37E-05	-1.66	4.39E-14	-3.56
PPARGC1A	10891	219195_at			5.49E-05	-1.14	2.15E-11	-2.66
SLC26A3	1811	215657_at			6.99E-08	-2.66	6.17E-14	-4.93
SP1B	6689	205861_at	T01401	Ets	1.92E-11	-2.71	4.08E-13	-2.03
SSBP2	23635	203787_at			1.93E-07	-1.23	1.29E-12	-2.47
VDR	7421	204254_s_at	T00885	Cys4 zinc finger of nuclear receptor type	2.43E-06	-1.20	4.03E-08	-1.36
ZBTB16	7704	205883_at		C2H2 zinc finger ^g	6.86E-08	-1.32	6.74E-13	-1.36
ARNTL2	56938	220658_s_at		Basic helix-loop-helix ^g	1.74E-05	1.58	2.28E-06	1.93
BHLHB2	8553	201170_s_at		Basic helix-loop-helix ^g	5.07E-08	1.96	1.29E-11	2.01
CBFB	865	202370_s_at	T02259	CBF_beta	2.12E-06	1.32	1.49E-13	1.49
CBX4	8535	206724_at			8.15E-05	1.11	9.62E-10	1.71
CEBPB	1051	212501_at		bZIP ^g	1.83E-05	1.00	6.84E-13	1.59
DENMT1	1786	201697_s_at		Zinc finger ^g	2.80E-05	1.18	7.61E-11	1.44
E2F3	1871	203693_s_at	T01545	Fork head/winged helix	2.46E-09	1.59	6.60E-14	1.69
FOXA2	3170	210103_s_at	T02413	Fork head	3.12E-07	2.06	2.75E-05	1.80
FOXM1	2305	202580_x_at	T02516	Fork head	1.17E-07	2.29	5.87E-15	3.10
GTF2IRD1	9569	218412_s_at		TFII1 ^g	3.18E-12	2.79	3.00E-22	2.77
GTF3A	2971	215091_s_at		C2H2 zinc finger ^g	3.54E-06	1.61	7.57E-13	2.00
HIRA	7290	217427_s_at			6.99E-08	1.43	2.61E-06	1.13
HMGAI	3159	206074_s_at		HMG ^g	1.91E-08	1.57	1.02E-19	2.50
HMGBI	3146	200679_x_at		HMG ^g	1.08E-05	1.26	5.54E-09	1.32
MTA1	9112	211783_s_at		Zinc finger ^g	6.96E-06	1.35	2.12E-11	1.57
MYC	4609	202431_s_at	T00140	bHLH-ZIP	4.10E-06	1.99	6.10E-14	2.66
NFE2L3	9603	204702_s_at		bZIP ^g	5.02E-07	1.80	5.15E-24	3.06
NME2	4831	201268_at	T00706		5.95E-09	1.08	2.39E-19	1.26
NPM1	4869	221923_s_at			5.22E-08	1.76	1.16E-12	1.59
PHB	5245	200658_s_at			5.01E-07	1.17	7.57E-10	1.25
POLR3K	51728	218866_s_at		Zinc finger ^g	8.15E-05	1.00	3.67E-06	1.12
RUNX1	861	209360_s_at	T01067	Runt	1.86E-05	1.30	3.34E-07	1.35
SCML1	6322	218793_s_at			1.32E-05	1.74	3.67E-07	1.68
SMARCA4	6597	213720_s_at		Bromo domain ^g	7.53E-07	1.11	2.42E-12	1.15
SMARCC1	6599	201074_at		Myb-like DNA-binding region ^g	8.84E-07	1.28	3.98E-11	1.15
SOX4	6659	213668_s_at	T01277	HMG	2.15E-07	2.84	1.06E-27	4.42
SOX9	6662	202935_s_at	T01853	HMG	1.38E-09	3.07	6.29E-27	3.91
TEAD4	7004	41037_at		TEA DNA-binding domain ^g	7.81E-10	2.24	2.99E-27	3.58
TFDP1	7027	212330_at	T01548	Fork head	7.04E-05	1.12	5.24E-07	1.21
TGIF	7050	203313_s_at	T04076	Homeo	1.17E-07	1.61	3.83E-20	2.44
THRAP4	9862	213043_s_at			2.51E-06	1.14	4.09E-15	1.59
TRIB3	57761	218145_at			1.66E-06	2.17	9.39E-20	3.73
TRIM29	23650	202504_at		Zinc finger ^g	6.99E-08	3.84	3.50E-11	4.39
TRIP13	9319	204033_at			2.40E-08	2.37	4.76E-23	3.32
ZNF238	10472	212774_at	T05040	C2H2-type zinc finger ^g	8.98E-07	1.38	6.55E-09	1.24
ZNF263	10127	203707_at		C2H2-type zinc finger ^g	3.97E-06	1.05	1.58E-16	1.46
ZNF593	51042	204175_at		C2H2-type zinc finger ^g	6.99E-08	1.45	3.32E-24	2.51

^aThe 'HG_UI33A' data set consists of 10 normal mucosa and 80 colon cancer samples. ^bThe 'HG_UI33 plus 2.0' data set consists of 10 normal mucosa and 344 colorectal cancer samples. ^cAffymetrix GeneChip 'HG_UI33A' and 'HG_UI33 plus 2.0' probe set identifiers. ^dAccording to TRANSFAC[®] 7.0 - Public (<http://www.gene-regulation.com/pub/databases.html>). ^eBenjamini and Hockberg-corrected 'Two Class Unpaired' test for difference in expression level between normal mucosa and cancer samples. ^fFold change (on log₂ scale) = the average log value of the cancer samples subtracted the average log value of the normal mucosa samples. ^gCharacteristic transcription factor domains according to the Uniprot database (<http://www.uniprot.org>).

stage II to III ($P = 0.593$, Fisher's exact test). To test if the E2F3 expression level followed a stage-specific trend, we applied a non-parametric test for trend (an extension of the Wilcoxon rank-sum test (Cuzick, 1985)) that did not reach significance ($P = 0.183$). Taken together the data indicate that there is no tight association between the E2F3 protein level and TNM stage. Likewise, our survival analysis did not identify any relationship between the E2F3 protein level and overall survival (data not shown).

In Supplementary Table 3B, correlations of E2F3 with other histopathological parameters are shown.

TF expression in microsatellite stable and unstable colon cancers

Two major molecular subgroups of CRC have been discerned - MSS and MSI cancers. As the cellular processes responsible for




Figure 1 E2F3 expression detected by immunohistochemistry. E2F3 IHC analysis of the commercial TMA, COCA 912-5-OL, containing normal mucosa as well as benign and malignant colorectal specimens demonstrated that although E2F3 was not expressed by normal epithelial cells (**A**) E2F3 was found *de novo* synthesised by the majority of the investigated neoplastic tissues (**B** and **C**). The subcellular localisation of the *de novo* synthesised E2F3 protein was in some tumours found to be primarily nuclear (**B**) and cytoplasmic in others (**C**). Adenocarcinomas with no E2F3 staining (negative) were also observed, though only rarely (**D**). These were very similar to the 'no primary' antibody negative control (**E**). The frequency and intensity of E2F3 protein expression (combining nuclear and cytoplasmic staining) in adenoma, adenocarcinoma and metastasis samples were significantly higher than in normal mucosa (**F**). The same was the case when nuclear and cytoplasmic staining was evaluated individually (data not shown). The E2F3 IHC staining was evaluable and scored in 70 of the 71 tissue cores in the commercial TMA. P-values correspond to Fisher's exact tests. ADC = adenocarcinoma. All images are $\times 20$. Staining: brown, E2F3; blue, haematoxylin counterstain.

both the similarities and differences between the MSI and MSS subgroups are likely to be regulated by TFs, we wanted to investigate the expression patterns of the deregulated TFs in MSS

and MSI cancers. To avoid tumour site from becoming a confounding factor, the analysis was restricted to colon cancers. This was motivated by the observation that MSI occurred more

Table 2 Transcription factors associated with MSI status, recurrence of stage II CRC and Wnt signalling

TF transcript level in	Up	Down
MSI relative to MSS	<i>ARNTL2, HIS1</i>	<i>CBFB, FOXA2, GTF2IRD1, GTF3A, HMGB1, RUNX1, SMARCC1, SOX4, SOX9, ZNF238</i>
Recurrent relative to non-recurrent stage II MSS cancers	<i>SOX4, TRIM29</i>	<i>KLF4</i>
Recurrent relative to non-recurrent stage II MSI cancers	<i>MAF, KLF4, ZBTB16</i>	<i>FOXMI, GTF3A, HIS1, NPM1, PHB, POLR3K, SMARCA4, TRIB3, TRIP13, VDR</i>
Cells with inactive Wnt signalling relative to cells with active Wnt signalling	<i>BHLHB2, HIS1, SSBP2, TRIM29</i>	<i>ARNTL2, MYC, SMARCA4, SOX4, SOX9, TEAD4, TGIF</i>

CRC = colorectal cancer; MSS = microsatellite stable; MSI = microsatellite instable. For detailed information on the sample sets investigated, the sizes of the fold changes observed and the statistical tests applied see Supplementary Tables 6–8.

frequently in colon (24%) than rectal cancer (12.5%) in our 'HG_U133 plus 2.0' sample set. Similar observations have been reported earlier (Ikeda *et al*, 2001). Naturally, only colon cancers for which the MSS/MSI status was known were included. Hence, from the 'HG_U133A' sample set, 76 of 80 colon cancers (51 MSS and 25 MSI) were included and from the 'HG_U133 plus 2.0' data set, 275 of 288 colon cancers (209 MSS and 66 MSI). To exclude that TNM stage distribution was a confounding factor, we used Fisher's exact tests to compare the distribution of TNM stages in the MSS and MSI subgroups. No significant differences were observed ($P > 0.05$).

Comparison of the MSS and MSI subgroups revealed that 12 of the 51 TFs were differentially expressed ($P < 0.05$, Benjamini and Hockberg-corrected 'Two class unpaired' test) in both data sets (Table 2 and Supplementary Table 6). Ten TFs showed lower, and two higher, expression in MSI relative to MSS cancer. A comparison of the expression levels of the 12 TFs in normal mucosa and MSS and MSI cancers revealed that *FOXA2* was significantly ($P < 0.01$) deregulated in MSS but not MSI cancers explaining why it was found to be differentially expressed between MSS and MSI. The remaining 11 TFs were all deregulated (normal to cancer) in both cancer subgroups (in the same direction), but the degree of deregulation differed explaining why they were found to be differentially expressed between MSS and MSI (data not shown).

TF expression in relation to recurrence of stage II CRC

Deregulation of TFs may lead to the development of cancer and progression of disease (Look, 1997; Nesbit *et al*, 1999). Along these lines we speculated if the transcriptional level of any of the identified TFs (Table 1) might be involved in determining the metastatic capacity of primary tumours. To test this hypothesis, we investigated transcriptional profiles of two series of stage II CRCs (an MSS and an MSI series), which were selected from our set of 287 stage II 'HG_U133 plus 2.0' transcription profiles. Twenty-seven cases were excluded based on the following criteria: missing MSS/MSI status ($n = 11$), missing follow-up ($n = 6$), follow-up < 40 months ($n = 1$) or distant recurrence to sites other than liver or lungs ($n = 9$). The remaining 260 cases were divided into two series based on their MSS/MSI status. None of the included cases had received adjuvant therapy. The stage II MSS series consisted of 173 non-recurrent cases with a median duration of follow-up of 59.8 months (range 43.3–145.6 months) and 22 recurrent cases, that is histologically verified liver and/or lung metastases, with a median duration of follow-up of 16.7 months (range 4.9–78.7 months). Similarly, the MSI series consisted of 56 non-recurrent

cases with a median duration of follow-up of 59.8 months (range 51.1–109.2 months) and nine recurrent cases with a median duration of follow-up of 30.0 months (range 1.2–65.9 months). Unpaired *t*-tests indicated that three of the 51 TFs were significantly associated ($P < 0.05$) with recurrence of stage II MSS cancer and 13 with recurrence of MSI stage II cancer (Table 2 and Supplementary Table 7). From a recent report we extracted Affymetrix HG_U133A transcriptional profiles of 25 non-recurrence and 25 recurrence (liver metastases) stage II MSS colon cancers (Barrier *et al*, 2006). By analysing this independent data set one of the three significant TFs (*SOX4*) from our MSS series was validated ($P = 0.0039$, unpaired *t*-test). The other two TFs did not reach significance. To our knowledge, no publicly available data set of stage II MSI CRCs with follow-up information exists. Hence, we have not been able to validate the 13 candidate markers of recurrence of stage II MSI cancer.

Next we investigated the association between the *SOX4* transcript level and recurrence-free survival. To enable survival analysis, the *SOX4* expression data were dichotomised with the highest tertile classified as high and the lower two tertiles classified as low. This cutoff was set based on associations within the MSS stage II CRC cohort of this study before analysing the validation cohort from Barrier *et al* (2006). As expected, the patients having an *SOX4* expression level in the highest tertile experienced a significantly higher incidence of recurrence ($P = 0.005$, χ^2 test) and a shorter recurrence-free survival (Figure 2A, log-rank test $P = 0.0083$ and univariate cox regression analysis $P = 0.01$; hazard ratio 2.0; 95% CI, 1.18–3.51). Notably, this association was only observed in our MSS series (Table 2), consistent with *SOX4* being differentially expressed between MSS and MSI tumours (Table 2). In the validation data set from Barrier *et al* (2006), *SOX4* expression in the upper tertile was also associated with a significantly higher incidence ($P = 0.005$, Fisher's exact test) of recurrence and a shorter recurrence-free survival (log-rank test $P = 0.0092$ and univariate cox regression analysis $P = 0.01$; hazard ratio 2.7; 95% CI, 1.2–6.0). Recurrence-free survival as a function of *SOX4* expression is plotted in Figure 2B. Subsequently, we wanted to investigate if the *SOX4* transcripts observed in cancer were also translated into protein. To address this question we returned to our comparisons of normal mucosa and adenocarcinomas, which demonstrated increased transcript levels in the adenocarcinomas (Table 1). We then performed a similar analysis at the protein level by applying *SOX4* IHC to a custom-made stage II TMA. The IHC staining was evaluable in 37 normal mucosa and 49 adenocarcinoma tissue cores (all from patients independent from the cohort investigated by transcriptional profiling). In agreement with the transcript analysis, IHC revealed that both the frequency and the expression level of *SOX4* protein were generally increased in adenocarcinomas, $P < 0.001$ Fisher's exact test (Figure 2C–H). Furthermore, the IHC analysis demonstrated that the *SOX4* protein found in the tumours was primarily of cancer cell origin (Figure 2D and E). We did not have recurrence nor survival information for the patients in the stage II TMA. Consequently, we could not evaluate if the *SOX4* protein level could also predict recurrence of stage II CRC. Nor could we analyse if it was associated with survival. However, this would be interesting to investigate in a future study.

CBFB and SMARCC1 protein expression and association with overall survival

Of the TFs not reported earlier to be associated with CRC, we selected CBFB and SMARCC1 for IHC analysis based on the availability of antibodies for which the specificity could be validated in western blot analyses. To investigate CBFB and SMARCC1 protein expression in normal and neoplastic tissues, IHC was applied to a commercial TMA (COCA 912-5-OL) containing tissue biopsies covering normal mucosa, adenoma,




Figure 2 Analysis of SOX4 transcript and protein expression levels. Shown are censored Kaplan–Meier curves for recurrence-free survival of MSS stage II CRC according to the transcriptional expression level of SOX4 as measured by microarray expression profiling in this study (**A**) and the study by Barrier *et al* (2006) (**B**). The *P*-values correspond to the log-rank test. To investigate whether the SOX4 protein expression level changed from normal mucosa to adenocarcinoma, IHC was applied to a custom-made stage II TMA. The TMA tissue cores were not scored if they were missing, or contained fewer than 10 cancer cells, or demonstrated significant tissue or IHC staining artefacts. Hence, only 49 of the 51 adenocarcinoma and 37 of the 49 normal mucosa cores in the TMA were scored. In the majority of the normal mucosa samples, SOX4 was either not (**C**) or only weakly expressed. By contrast, a strong SOX4 staining was observed in more than 40% of the stage II adenocarcinomas. Often, the SOX4 protein was localised both in the cytoplasm and in the nucleus of the cancer cells. In some adenocarcinomas, the SOX4 staining was strongest in the nucleus (**D**), whereas in others, the cytoplasm and the nucleus were stained equally strong (**E**). Adenocarcinomas with no SOX4 staining (negative) were also observed, though only rarely (**F**). These were highly similar to the 'no primary' antibody negative control (**G**). The distribution of SOX4 IHC scores (combined nuclear and cytoplasmic staining) showed that both the frequency and the intensity of SOX4 staining were increased in the adenocarcinomas compared with those in the normal mucosae (**H**). The same was the case when the nuclear and cytoplasmic IHC scores were analysed individually (data not shown). The *P*-values were calculated using the χ^2 test. All IHC images are $\times 20$. Staining: brown, SOX4; blue, haematoxylin counterstain.

adenocarcinoma and liver metastases. No CBFβ protein expression was observed in normal epithelia (Figure 3A). SMARCC1 was found to be weakly expressed in the basal half of the normal colonic crypts (Figure 4A). CBFβ was observed both in the nucleus and in the cytoplasm of the neoplastic cells, whereas SMARCC1 was observed only in the nucleus in both normal and neoplastic cells (Figure 3B and C and 4B, respectively). A comparison of IHC

staining for CBFβ and CD45 (a pan-leukocyte marker) indicated that CBFβ was also expressed by a subset of stromal cells, in particular lymphocytes, including lymphocytes infiltrating both normal epithelia and cancer (Figure 3E). We then compared the staining frequencies observed in normal mucosa, adenoma, adenocarcinoma and liver metastasis. For simplicity, the nuclear and cytoplasmic CBFβ IHC scores were combined to a single CBFβ

score in these analyses. The frequency and intensity of CBF8 expression increased significantly ($P=0.01$, Fisher's exact test) from normal mucosa to adenoma and again from adenoma to

adenocarcinoma ($P<0.001$, Fisher's exact test). By contrast, the staining frequency in liver metastases was significantly lower than that in adenocarcinomas ($P<0.001$, Fisher's exact test) (Figure 3F).







Figure 3 CBF8 protein expression and the relation to survival. The CBF8 protein expression was investigated by IHC in normal mucosa, adenoma, adenocarcinoma and metastases using the commercial TMA COCA 912-5-OL. Tissue microarray tissue cores were not scored if they were missing, or contained fewer than 10 cancer cells or demonstrated significant tissue or staining artefacts. Hence, of the 71 tissue cores in the commercial TMA, 68 were scored for CBF8 expression. The IHC analysis showed that whereas CBF8 was not expressed by normal epithelial cells (A) CBF8 was found *de novo* synthesised by the majority of the investigated neoplastic tissues (B and C). The subcellular localisation of the *de novo* synthesised CBF8 protein was in some tumours found to be primarily nuclear (B) and cytoplasmic in others (C). Adenocarcinomas with no CBF8 staining (negative) were also observed (D). Often small intensely staining cells were seen in the stroma and infiltrating both the normal epithelia (A) and the cancer cells (C). Comparison of sections cut from the same biopsies and stained with CBF8 and CD45 (a pan-leukocyte marker) indicated that the small cells with intense CBF8 staining represent infiltrating leukocytes (E). The distribution of the CBF8 IHC scores in normal mucosa, adenoma, adenocarcinoma and metastases illustrates that CBF8 is *de novo* synthesised in neoplastic tissue and that the frequency and intensity of the staining (combined cytoplasmic and nuclear staining) increases from adenoma to adenocarcinoma, and then drops back down again in metastases (F). Similar results were reached when the cytoplasmic and nuclear staining were analysed individually (data not shown). *P*-values correspond to Fisher's exact tests. To investigate if the CBF8 protein level was correlated with overall survival, IHC was applied to a large custom-made TMA containing adenocarcinoma tissue cores from 1283 patients with available follow-up information. The CBF8 IHC staining was evaluable in 1009 of these patients. Shown in (G) are censored Kaplan–Meier curves as a function of the CBF8 IHC scores (nuclear and cytoplasmic scores combined). The individual survival curves for patients with negative and weak IHC scores were very similar, and they were therefore treated as one group. Similar results were reached when the cytoplasmic and nuclear staining were analysed individually (data not shown). The *P*-value corresponds to the log-rank test comparing the survival curves. See Supplementary Table 3A for a summary of the clinical characteristics and follow-up information available for the 1009 patients. See Supplementary Table 3C for the distribution of the 1009 IHC scores and their correlations with the available clinicopathological parameters. Arrow heads: infiltrating lymphocytes. Arrows: lymphoid nodules. All images are $\times 20$. Staining: brown, CBF8 or CD45 as indicated; blue, haematoxylin counterstain.

Figure 4 SMARCC1 protein expression and the relation to survival. The SMARCC1 protein expression was investigated by IHC in normal mucosa, adenoma, adenocarcinoma and metastases using the commercial TMA COCA 912-5-OL. Tissue microarray tissue cores were not scored if they were missing, or contained fewer than 10 cancer cells or demonstrated significant tissue or staining artefacts. Hence, of the 71 tissue cores in the commercial TMA, 68 were scored for SMARCC1 expression. The IHC analysis showed that in normal colon mucosa, SMARCC1 was weakly expressed in the lower third of the crypts (A). The inset in (A) represents an IHC analysis of the same specimen but without the counterstain, making the SMARCC1 staining at the bottom of the crypts stand out more clearly. In contrast to the normal mucosa, the SMARCC1 staining seen in the neoplastic tissues was often more intense and uniformly distributed (B). Neoplastic tissues with no SMARCC1 staining (negative) were also observed (C). The subcellular localisation of the SMARCC1 protein was in both the normal epithelial cells and in the neoplastic cells restricted to the nucleus (A and B). As SMARCC1 was already expressed by the normal mucosa, comparisons of the SMARCC1 IHC scores in normal mucosa, adenocarcinoma and metastases revealed no significant differences (D). *P*-values correspond to Fisher's exact tests. To investigate if the SMARCC1 protein level was correlated with overall survival, IHC was applied to a large custom-made TMA containing adenocarcinoma tissue cores from 1283 patients with available follow-up information. The SMARCC1 IHC staining was evaluable in 989 of these patients. Shown in (E) are censored Kaplan–Meier survival curves as a function of the SMARCC1 IHC scores. The individual survival curves for patients with negative and weak IHC scores were very similar and they were therefore treated as one group. The *P*-value corresponds to the log-rank test comparing the survival curves. See Supplementary Table 3A for a summary of the clinical characteristics and follow-up information available for the 989 patients. See Supplementary Table 3D for the distribution of the 989 IHC scores and their correlations with the available clinicopathological parameters. All images are $\times 20$. Staining: brown, SMARCC1; blue, haematoxylin counterstain.



Overall, the IHC analysis indicated that the CBF protein level was increased in tumours compared with normal mucosa. This was in agreement with the transcriptional data presented above.

SMARCC1 showed weak staining in the basal half of the normal crypts in 9 of 10 specimens. In contrast, only 4 of 10 adenomas showed staining. Contrary to the normal mucosa, the adenomas were uniformly stained. The frequency and

intensity of SMARCC1 staining increased borderline significantly ($P = 0.078$, Fisher's exact test) from adenoma to adenocarcinoma, but not from adenocarcinoma to liver metastases (Figure 4D). Generally, the staining intensities observed in the neoplastic tissues were more intense than in the normal mucosa (Figure 4A and B). This combined with a more uniform staining pattern indicated that the overall SMARCC1 protein level was

Table 3 Univariate and multivariate analysis for overall survival (Cox proportional hazard regression model)

Factor	Patients (n = 959) ^a	Univariate analysis			Multivariate analysis		
		HR	95% CI	P-value	HR	95% CI	P-value
Age at surgery (years)							
<65	317	1	(Reference)		1	(Reference)	
>65	642	1.69	1.38–2.06	<0.001	1.76	1.44–2.16	<0.001
Sex (M/F)							
Male	503	1	(Reference)		1	(Reference)	
Female	456	1.36	1.14–1.62	0.001	1.35	1.13–1.62	0.001
Differentiation ^b							
Well	13	1	(Reference)		1	(Reference)	
Moderate	821	3.02	0.97–9.41	0.056	1.89	0.60–5.99	0.276
Poor	116	5.05	1.59–16.04	0.006	2.9	0.90–9.38	0.074
Tumour location							
Right colon	332	1	(Reference)		—	—	—
Left colon	302	0.81	0.65–1.00	0.053	—	—	—
Rectum	325	0.85	0.69–1.05	0.131	—	—	—
Mucinous ^b							
No	883	1	(Reference)		—	—	—
Yes	70	1.01	0.85–1.20	0.89	—	—	—
UICC TNM stage							
I	128	1	(Reference)		1	(Reference)	
II	369	2.65	1.72–4.07	<0.001	2.33	1.51–3.60	<0.001
III	462	6.59	4.35–9.99	<0.001	5.88	3.87–8.95	<0.001
SMARCC1 staining							
Negative/weak	576	1	(Reference)		1	(Reference)	
Strong	383	0.82	0.68–0.98	0.029	0.95	0.78–1.14	0.57
CBFB staining							
Negative/weak	491	1	(Reference)		1	(Reference)	
Strong	468	0.72	0.61–0.86	<0.001	0.79	0.65–0.95	0.011

HR = hazard ratio; TF = transcription factor; 95% CI = 95% confidence interval. ^aTo enable comparison of CBFB and SMARCC1, only patients with evaluable IHC staining for both TFs were included. Hence of the 1283 patients from the large custom-made TMA with available follow-up information, only 959 were included in the analysis. ^bPatients with missing values were excluded from the analysis.

generally higher in neoplastic tissue than in normal mucosa. This is in accordance with the SMARCC1 transcriptional data presented above.

To investigate the possible associations between the protein levels of CBFB and SMARCC1 and the TNM stages and overall survival, IHC was applied to a large custom-made TMA with stage I–III adenocarcinomas for which follow-up information was available. For both TFs, the frequency of strong staining appeared to decrease with increasing TNM stage; however, the tendencies were insignificant in both instances ($P > 0.05$, Fisher's exact test; Supplementary Tables 3C and D). When a less-stringent test for trend (an extension of the Wilcoxon rank-sum test (Cuzick, 1985)) was applied, the tendencies were significant; $P = 0.029$ and $P = 0.026$ for CBFB and SMARCC1, respectively (Supplementary Tables 3C and D). Next, the possible correlations between CBFB and SMARCC1 protein levels and overall survival were investigated. Kaplan–Meier survival curves are shown in Figures 3G and 4E. Patients with tumours showing strong staining had a significantly longer survival rate than patients with negative or weak scoring tumours (log-rank test; CBFB $P = 0.0001$; SMARCC1 $P = 0.0275$). As both CBFB and SMARCC1 had shown weak correlations with TNM stage, the Kaplan–Meier survival analyses were repeated and this time was stratified by TNM stage (Supplementary Figure 2). Bivariate Cox proportional hazard regression analyses showed that while the CBFB protein level remained a significant prognostic factor after stratification for

TNM stage ($P = 0.002$), the SMARCC1 protein level was only borderline significant ($P = 0.073$) (Supplementary Figure 2). To elaborate the analysis, it was extended from a bi- to a multivariate analysis including all the available variables that were significant in univariate analysis (i.e. age at surgery, sex, differentiation grade, TNM stage, CBFB staining and SMARCC1 staining). The multivariate analysis showed that while the CBFB protein level remained a significant prognostic factor after stratifying for all other available risk parameters ($P = 0.011$) the SMARCC1 protein level did not (Table 3).

TF expression in relation to Wnt signalling

The Wnt-signalling pathway is aberrantly activated in the majority of CRCs and contributes directly to malignant transformation by influencing the transcript levels of numerous genes (van de Wetering *et al*, 2002; de Lau *et al*, 2007). To investigate if changes in the activity of the Wnt-signalling pathway could influence the expression level of any of the 51 TFs we utilised a colon carcinoma model system based on LS174T cells. The model system was engineered so that Wnt signalling mediated by β -catenin/TCF could be abrogated on demand by induction of dnTCF1 (van de Wetering *et al*, 2002), a naturally occurring inhibitor of Wnt signalling (Waterman, 2004). Using two different microarray platforms, the transcript levels of all 51 TFs were measured at 0

and 12 h after dnTCF1 induction. Induction was validated directly and indirectly by qRT-PCR. Directly, by demonstrating increased levels of dnTCF1 transcript, and indirectly, by demonstrating downregulation of *c-Myc*, a well-known target of the inhibited β -catenin/TCF complex (Supplementary Figure 3). Both microarray platforms consistently showed deregulation of 11 TFs (seven downregulated, including *c-MYC*, and four upregulated) in cells in which Wnt signalling was inactivated (Table 2 and Supplementary Table 8). In the majority of CRCs, Wnt signalling is abnormally active; consequently, we would expect genes downregulated by Wnt inactivation to be upregulated in cancer and vice versa for genes upregulated by Wnt inactivation. For 9 of the 11 Wnt-regulated TFs, this was exactly what we observed (Supplementary Table 8). The seven TFs downregulated by Wnt inactivation were all upregulated in cancer, and two of the four TFs upregulated by Wnt inactivation (*HIS1* and *SSBP2*) were downregulated in cancer. The expression levels of the remaining 40 TFs did not consistently follow Wnt-signalling activity. Hence, for ~20% of the 51 TFs a likely cause for the observed deregulation in cancer is abnormal Wnt signalling.

DISCUSSION

This study reports the results from a thorough analysis of TF expression changes in CRC. Our analysis of array-based transcriptional profiles of 20 normal mucosa and 424 CRC samples indicated that 51 TFs were significantly deregulated in CRC. The high number of deregulated TFs is consistent with the dramatic transcriptional differences observed between cancer cells and normal epithelia (Birkenkamp-Demtroder *et al*, 2002; Kruhoffer *et al*, 2005). Among the 51 candidate TFs several were already known to be deregulated in CRC, for example *c-MYC* (He *et al*, 1998) and *SOX9* (Blache *et al*, 2004), and also many for which this information was novel. Of the latter, we selected four and validated their deregulation by qRT-PCR (E2F3) and/or IHC (E2F3, *SOX4*, *CBFβ* and *SMARCC1*). For some of the TFs not previously reported to be deregulated in CRC, the involvement in the tumorigenesis of other cancers has been well established for example, *SOX4* in bladder cancer and *CBFβ* in acute myeloid leukaemia (Kundu *et al*, 2002; Aaboe *et al*, 2006). Altogether, this indicates that many of the identified TFs are likely to play a role in the pathogenesis of CRC.

The RB/E2F pathway has been shown to be mutationally disrupted in many human cancers, but not in CRC (Nevins, 2001). It is still a matter of debate what role, if any, the RB/E2F pathway plays in the development of CRC (Hildebrandt *et al*, 2000; Nevins, 2001). Consistent with earlier studies not finding E2F3 in normal lung, bladder and prostate tissue (Feber *et al*, 2004; Foster *et al*, 2004; Cooper *et al*, 2006) we found that E2F3 was generally not expressed by the normal colon epithelia. In contrast, our analysis of CRC specimens showed high E2F3 transcript and protein levels, and revealed a dramatic reduction in the *RB1/E2F3* transcript ratio. We hypothesise that this reduction entails that the E2F inhibitor RB1 is titrated out and that the G1/S-transition checkpoint consequently is overridden, enabling the cancer cells to proliferate. We found no correlation between the E2F3 expression level and TNM stage or survival. This probably indicates that E2F3 is upregulated early in tumour development and hence not directly related to the outcome of the disease. Our data indicate that RB/E2F pathway inactivation may play an important role in CRC pathogenesis even though the mechanism of inactivation is different than in most other cancers.

To study if the 51 deregulated TFs were also involved in other aspects of CRC pathogenesis we investigated their transcript levels in the transcriptionally and clinically different MSS and MSI tumour subgroups. Twelve TFs were found to be differentially expressed between MSI and MSS tumours. However, compared

with normal mucosa, 11 of these were deregulated in both MSS and MSI tumours making it difficult to judge if the differences between MSS and MSI have any biological consequences. The twelfth TF (*FOXA2*) was deregulated in the MSS tumours only. Hence, *FOXA2* is likely to be regulating some of the many transcripts that are differentially expressed between MSS and MSI tumours.

We next investigated if the transcript levels of any of the selected 51 TFs were capable of predicting outcome of stage II CRC. The analyses indicated that three were putatively associated with recurrence of MSS stage II cancer and 13 putatively with recurrence of MSI stage II cancer. The higher number of candidates associated with recurrence of MSI cancer may be caused by a higher false-positive rate due to the limited number of samples in the MSI series (9 recurrent and 56 non-recurrent) compared with the MSS series (22 recurrent and 173 non-recurrent). The availability of transcriptional profiles from an independent cohort of stage II MSS cancer patients (Barrier *et al*, 2006) enabled us to investigate if any of the three MSS candidates could be validated. To our knowledge, no such data set is public available for MSI cancer; hence, the MSI candidates still await validation. Of the three MSS candidates only *SOX4* was also associated with recurrence in the independent cohort. In both cohorts, a high *SOX4* transcript level was significantly associated with recurrence of stage II MSS cancer and shorter recurrence-free survival. We only observed the association in MSS cancers consistent, with *SOX4* being differentially expressed between MSS and MSI tumours. By IHC analysis we demonstrated that the increased *SOX4* transcript levels, observed in CRC compared with normal mucosa, also translated to the protein level. Moreover, the IHC analysis revealed that the observed expression difference was cancer cell specific and not related to stromal changes. In summary, high *SOX4* transcript levels identify patients with a high risk of recurrence. These patients are likely to benefit from a more aggressive therapy than the standard treatment offered to stage II patients today. This study is not the first to link *SOX4* expression and clinical outcome of cancer. A recent study reported that the *SOX4* expression level correlated with survival in patients with urinary bladder cancer (Aaboe *et al*, 2006).

In normal cells, the transcriptional levels of TFs are tightly controlled by a network of signalling pathways. Several studies have shown that deregulation of pathways, for example, the K-ras/B-raf and Notch pathways, is a mechanism for deregulation of TFs in cancer (Sancho *et al*, 2004). We speculated whether pathway deregulation could be the mechanistic explanation for the altered expression patterns of the selected TFs. Mutational activation of the Wnt pathway occurs in 80–90% of all CRC cases and the pathway is thus a likely cause for deregulation of one or more of the TFs. Indeed, our array-based transcriptional profiling analysis of an inducible colon carcinoma Wnt-model system corroborated our hypothesis by indicating that 11 (~20%) of the 51 TFs were Wnt-responsive genes. Importantly, these observations are supported by an earlier study that reported 5 of our 11 candidate Wnt-target TFs (*TGIF*, *SOX9*, *MYC*, *SOX4* and *TEAD4*) to be Wnt targets (Van der Flier *et al*, 2007). Collectively, our data indicate that deregulation of signalling pathways can lead to deregulation of TFs; this is likely to lead to deregulation of further signalling pathways, and in the end possibly to cellular transformation.

In the majority of CRC specimens we found the transcript and protein levels of both *CBFβ* and *SMARCC1* increased compared with normal mucosa. Importantly, the observed differences were related to altered expression in the cancer cells and not the stroma cells. Univariate survival analysis revealed that patients with high protein levels of *CBFβ* and *SMARCC1* had a significantly longer overall survival rate than patients with low levels. Multivariate analysis further showed that the prognostic power of *CBFβ* was independent of well-established prognostic factors, including TNM stage and differentiation grade. In keeping with the association between low levels of *CBFβ* protein and poor survival, we observed

that cases with negative/weak CBF_B protein levels were significantly enriched in metastasis cases compared with primary adenocarcinomas. Our transcript analyses of *CBFB* and *SMARCC1* did not reveal any association, not even a trend, to recurrence of stage II cancer. We cannot explain why the protein but not the transcript level is associated with outcome. But it should be noted that the transcript analyses were performed using stage II cancers and time to recurrence data, whereas the protein analyses were performed using all TNM stages and overall survival data. This might in part explain the discrepancy. Consistent with earlier reports, we found CBF_B protein both in the cytoplasm and the nucleus of the neoplastic cells (Tanaka *et al*, 1997). These locations are in agreement with the known function of CBF_B, which constitutes half of the core-binding factor TF complex. Upon stimulation, cytoplasmic CBF_B dimerises with the one of the CBF α factors (RUNX1–3), forming the core-binding factor complex, which in turn translocates to the nucleus and executes its TF function (Speck and Gilliland, 2002). Interestingly, *RUNX1* is one among the TFs that we found are upregulated. *SMARCC1* is a core member of the SWI/SNF chromatin remodelling complex, and hence performs its function in the nucleus (Roberts and Orkin, 2004). In agreement with this, and with a previous report on the subcellular location of *SMARCC1* in prostate cancer, we found *SMARCC1* to be located in the nucleus (Heeboll *et al*, 2008). It is worth noting that in recent reports, the SWI/SNF chromatin remodelling complex, in line with our observations (*SMARCC1*), has become increasingly recognised for its role in tumour suppression (Roberts and Orkin, 2004; Nagl *et al*, 2007). To our knowledge, CBF_B has not previously been associated with tumour suppressor activity. However, our data indicate that in CRC, possibly through interaction with *RUNX1* and the formation of the core-binding factor complex, CBF_B has this function. At first it may seem peculiar that high expression levels of genes, generally upregulated in tumours, can lead to prolonged patient survival; there are, however, mechanisms that could explain these findings. For example, as part of their natural defence mechanisms, normal cells will, when exposed to carcinogens, upregulate genes that suppress tumour development. Hence, during tumour development there will be selection towards clones that either simply

downregulate these genes, or inactivate the signalling pathways through which they function. In cancers produced by the latter scenario, the tumour suppressor genes are upregulated but the cancer cells no longer respond to the signal. Genes involved in DNA damage response are examples of this (Bartkova *et al*, 2005).

In conclusion, we have identified 51 TFs that at the transcript level are deregulated in CRC compared with normal mucosa. Among these, *E2F3* is a key component of the RB/E2F G1/S transition checkpoint, indicating that inactivation of this checkpoint may be critical for the development of CRC. We showed that pathway deregulation, exemplified by the Wnt pathway, is a likely mechanism causing the observed TF deregulations. Furthermore, we found that the transcript levels of a subset of the TFs were associated with microsatellite status. For *E2F3*, *SOX4*, *CBFB* and *SMARCC1*, the transcript analyses were corroborated by an in-depth IHC analysis not only confirming their increased expression level, but also demonstrating their expression by the cancer cells. Finally, we showed that three of the identified TFs have prognostic potential. A high transcript level of *SOX4* predicts recurrence of stage II CRC, whereas high protein levels of *SMARCC1* and CBF_B predict long-term survival of CRC.

ACKNOWLEDGEMENTS

We thank Dr Marianne Hokland for the CD45 antibody and Dr Francisco Mansilla for assistance with immunoblotting. This study was funded by the Regulatory Genomics Project of the European Union (Torben Falck Ørntoft), the Danish Research Council (Torben Falck Ørntoft) and the John and Birthe Meyer Foundation (Torben Falck Ørntoft).

Conflict of interest

The authors declare that there is no conflict of interest.

Supplementary Information accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>)

REFERENCES

- Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen FB, Thykjaer T, Sauter G, Jensen KM, Dyrskjot L, Orntoft T (2006) *SOX4* expression in bladder carcinoma: clinical aspects and *in vitro* functional characterization. *Cancer Res* **66**: 3434–3442
- Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. *Cancer Res* **64**: 5245–5250
- Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D, Lacaine F, Houry S, Huguier M, Franc B, Flahault A, Lemoine A, Dudoit S (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. *J Clin Oncol* **24**: 4685–4691
- Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldborg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* **434**: 864–870
- Birkenkamp-Demtroder K, Christensen LL, Olesen SH, Frederiksen CM, Laiho P, Aaltonen LA, Laurberg S, Sorensen FB, Hagemann R, Ørntoft TF (2002) Gene expression in colorectal cancer. *Cancer Res* **62**: 4352–4363
- Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, Clevers H, Jay P (2004) *SOX9* is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the *CDX2* and *MUC2* genes. *J Cell Biol* **166**: 37–47
- Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, Fletcher A, Roe T, Clark J, Joshi A, Norman A, Feber A, Lin D, Gao Y, Shipley J, Cheng SJ (2006) Nuclear overexpression of the *E2F3* transcription factor in human lung cancer. *Lung Cancer* **54**: 155–162
- Cuzick J (1985) A Wilcoxon-type test for trend. *Stat Med* **4**: 87–90
- de Lau W, Barker N, Clevers H (2007) WNT signaling in the normal intestine and colorectal cancer. *Front Biosci* **12**: 471–491
- Dyrskjot L (2003) Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics. *Expert Rev Mol Diagn* **3**: 635–647
- Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, Roe T, Kovacs G, Dennis N, Fisher C, Wooster R, Huddart R, Foster CS, Cooper CS (2004) Amplification and overexpression of *E2F3* in human bladder cancer. *Oncogene* **23**: 1627–1630
- Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS (2004) Transcription factor *E2F3* overexpressed in prostate cancer independently predicts clinical outcome. *Oncogene* **23**: 5871–5879
- Giacomini CP, Leung SY, Chen X, Yuen ST, Kim YH, Bair E, Pollack JR (2005) A gene expression signature of genetic instability in colon cancer. *Cancer Res* **65**: 9200–9205
- He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW (1998) Identification of *c-MYC* as a target of the APC pathway. *Science* **281**: 1509–1512
- Heeboll S, Borre M, Ottosen PD, Andersen CL, Mansilla F, Dyrskjot L, Orntoft TF, Tørring N (2008) *SMARCC1* expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. *Histol Histopathol* **23**: 1069–1076
- Hildebrandt B, Heide I, Thiede C, Nagel S, Dieing A, Jonas S, Neuhaus P, Rochlitz CF, Riess H, Neubauer A (2000) Lack of point mutations in

- exons 11–23 of the retinoblastoma susceptibility gene RB-1 in liver metastases of colorectal carcinoma. *Oncology* **59**: 344–346
- Ikeda Y, Oda S, Abe T, Ohno S, Maehara Y, Sugimachi K (2001) Features of microsatellite instability in colorectal cancer: comparison between colon and rectum. *Oncology* **61**: 168–174
- Kruhoffer M, Jensen JL, Laiho P, Dyrskjot L, Salovaara R, Arango D, Birkenkamp-Demtroder K, Sorensen FB, Christensen LL, Buhl L, Mecklin JP, Jarvinen H, Thykjaer T, Wikman FP, Bech-Knudsen F, Juhola M, Nupponen NN, Laurberg S, Andersen CL, Aaltonen LA, Orntoft TF (2005) Gene expression signatures for colorectal cancer microsatellite status and HNPCC. *Br J Cancer* **92**: 2240–2248
- Kundu M, Chen A, Anderson S, Kirby M, Xu L, Castilla LH, Bodine D, Liu PP (2002) Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. *Blood* **100**: 2449–2456
- Look AT (1997) Oncogenic transcription factors in the human acute leukemias. *Science* **278**: 1059–1064
- Nagl Jr NG, Wang X, Patsialou A, Van Scoy M, Moran E (2007) Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. *EMBO J* **26**: 752–763
- Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. *Oncogene* **18**: 3004–3016
- Nevins JR (2001) The Rb/E2F pathway and cancer. *Hum Mol Genet* **10**: 699–703
- Parkin DM (2001) Global cancer statistics in the year 2000. *Lancet Oncol* **2**: 533–543
- Roberts CW, Orkin SH (2004) The SWI/SNF complex—chromatin and cancer. *Nat Rev Cancer* **4**: 133–142
- Sancho E, Batlle E, Clevers H (2004) Signaling pathways in intestinal development and cancer. *Annu Rev Cell Dev Biol* **20**: 695–723
- Schepeler T, Mansilla F, Christensen LL, Orntoft TF, Andersen CL (2007) Clusterin expression can be modulated by changes in TCF1-mediated Wnt signaling. *J Mol Signal* **2**: 6
- Speck NA, Gilliland DG (2002) Core-binding factors in haematopoiesis and leukaemia. *Nat Rev Cancer* **2**: 502–513
- Tanaka Y, Watanabe T, Chiba N, Niki M, Kuroiwa Y, Nishihira T, Satomi S, Ito Y, Satake M (1997) The protooncogene product, PEBP2beta/CBFbeta, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures. *Oncogene* **15**: 677–683
- Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhoffer M, Laurberg S, Borre M, Wang K, Brunak S, Krainer AR, Topping N, Dyrskjot L, Andersen CL, Orntoft TF (2008) Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. *Mol Cell Proteomics* **7**: 1214–1224
- van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. *Cell* **111**: 241–250
- Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G, Clevers H (2007) The intestinal Wnt/TCF signature. *Gastroenterology* **132**: 628–632
- Wang Y, Jatkoet T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D (2004) Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. *J Clin Oncol* **22**: 1564–1571
- Waterman ML (2004) Lymphoid enhancer factor/T cell factor expression in colorectal cancer. *Cancer Metastasis Rev* **23**: 41–52
- Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. *Br J Cancer* **94**: 128–135
- Woodford-Thomas T, Thomas ML (1993) The leukocyte common antigen, CD45 and other protein tyrosine phosphatases in hematopoietic cells. *Semin Cell Biol* **4**: 409–418